David J. Moliterno
Gill Heart Institute and Division of Cardiovascular Medicine
University of Kentucky
Lexington
Kentucky
USA
Name/email consistency: high
- Advances in antiplatelet therapy for ACS and PCI. Moliterno, D.J. J. Interv. Cardiol (2008)
- Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. Moliterno, D.J., Chan, A.W. J. Am. Coll. Cardiol. (2003)
- A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. Moliterno, D.J., Hermiller, J.B., Kereiakes, D.J., Yow, E., Applegate, R.J., Braden, G.A., Dippel, E.J., Furman, M.I., Grines, C.L., Kleiman, N.S., Levine, G.N., Mann, T., Nair, R.N., Stine, R.A., Yacubov, S.J., Tcheng, J.E. J. Am. Coll. Cardiol. (2003)
- Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Moliterno, D.J., Yakubov, S.J., DiBattiste, P.M., Herrmann, H.C., Stone, G.W., Macaya, C., Neumann, F.J., Ardissino, D., Bassand, J.P., Borzi, L., Yeung, A.C., Harris, K.A., Demopoulos, L.A., Topol, E.J. Lancet (2002)
- Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. Moliterno, D.J. Am. Heart J. (2000)
- A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. Moliterno, D.J., Topol, E.J. Am. Heart J. (2000)
